Jordyn Sava is an assistant editor for Targeted Oncology™.
Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer Studies
June 3rd 2023Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.